Ceribell

EEG devices for monitoring brain activity

Mountain View, California, United States

About Ceribell

Ceribell focuses on developing medical devices that utilize electroencephalogram (EEG) technology to monitor brain activity. Their main product, the Ceribell EEG Headband and Recorder, is designed for use by trained healthcare providers in professional settings. These devices help gather important data about a patient's brain activity, which healthcare professionals can analyze to make informed treatment decisions, especially in urgent situations like Nonconvulsive Status Epilepticus (NCSE), where timely intervention is crucial. Unlike some other EEG devices, Ceribell's products do not provide diagnostic conclusions or automated alerts; they serve purely as data collection tools. Ceribell differentiates itself by emphasizing the speed and efficiency of data gathering, which is vital in critical care scenarios. The company's goal is to enhance the ability of healthcare providers to monitor and respond to neurological conditions effectively.

Mountain View, CaliforniaHeadquarters
2014Year Founded
$146.9MTotal Funding
SERIES_CCompany Stage
HealthcareIndustries
201-500Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Annual Bonus Opportunity
Company Equity
Phone/Internet Stipend

Risks

Emerging AI-powered EEG technologies increase competition, threatening Ceribell's market share.
Regulatory scrutiny on AI medical devices could lead to compliance costs and delays.
Scaling production post-IPO may cause supply chain bottlenecks, affecting delivery timelines.

Differentiation

Ceribell's EEG system is FDA cleared and requires no specialist interpreter.
The Brain Stethoscope function converts brainwaves to sound for easy seizure detection.
Ceribell's EEG system can be set up in 6 minutes by any healthcare provider.

Upsides

AI integration enhances Ceribell's diagnostic capabilities, providing a competitive market edge.
Growing EEG market demand due to rising neurological disorders benefits Ceribell's product sales.
Point-of-care testing trend supports adoption of Ceribell's portable EEG system.

Funding

Total raised$146.88 M
Latest valuation$265.00 M
StageSERIES_C